Page last updated: 2024-09-03

desloratadine and Autoimmune Urticaria

desloratadine has been researched along with Autoimmune Urticaria in 3 studies

Research

Studies (3)

TimeframeStudies, this research(%)All Research%
pre-19900 (0.00)18.7374
1990's0 (0.00)18.2507
2000's0 (0.00)29.6817
2010's2 (66.67)24.3611
2020's1 (33.33)2.80

Authors

AuthorsStudies
Lai, Y; Li, M; Tang, Y; Wen, Y1
Donnarumma, M; Gallo, R; Napolitano, M; Patruno, C1
Chen, M; Chen, W; Chen, X; Li, F; Li, J; Li, Q; Liu, Z; Peng, C; Su, J; Yan, S; Zhang, J; Zhang, W; Zhu, W1

Reviews

1 review(s) available for desloratadine and Autoimmune Urticaria

ArticleYear
Efficiency and safety of desloratadine in combination with compound glycyrrhizin in the treatment of chronic urticaria: a meta-analysis and systematic review of randomised controlled trials.
    Pharmaceutical biology, 2021, Volume: 59, Issue:1

    Topics: Anti-Inflammatory Agents; CD4-Positive T-Lymphocytes; CD8-Positive T-Lymphocytes; Chronic Urticaria; Drug Therapy, Combination; Glycyrrhizic Acid; Histamine H1 Antagonists, Non-Sedating; Humans; Immunoglobulin E; Loratadine; Randomized Controlled Trials as Topic

2021

Other Studies

2 other study(ies) available for desloratadine and Autoimmune Urticaria

ArticleYear
Salt-dependent aquagenic urticaria in children: Report of two cases.
    Pediatric allergy and immunology : official publication of the European Society of Pediatric Allergy and Immunology, 2018, Volume: 29, Issue:3

    Topics: Child; Chronic Inducible Urticaria; Female; Histamine H1 Antagonists, Non-Sedating; Humans; Loratadine; Skin Tests; Sodium Chloride; Urticaria

2018
C-reactive protein (CRP) rs3093059C predicts poor mizolastine response in chronic spontaneous urticaria patients with elevated serum CRP level.
    Experimental dermatology, 2019, Volume: 28, Issue:3

    Topics: Adolescent; Adult; Aged; Animals; Benzimidazoles; C-Reactive Protein; China; Chronic Disease; Chronic Urticaria; Female; Gene Expression; Genotype; HEK293 Cells; Histamine H1 Antagonists; Humans; Interleukin-6; Loratadine; Male; Middle Aged; Polymorphism, Single Nucleotide; Rats; Treatment Outcome; Tumor Necrosis Factor-alpha; Young Adult

2019